Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia

The following is an excerpt from a press release from Bioverativ. Read the entire press release here.  More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program Bioverativ Inc., a Sanofi company, joins the global hemophilia […]

FDA Grants Breakthrough Therapy Designation for Genentech's Hemlibra

The following is an excerpt from a press release from Genentech. Read the full press release here.  Genentech, a member of the Roche Group, announced today the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to HEMLIBRA for people with hemophilia A without factor VIII inhibitors. Breakthrough Therapy Designation is designed to accelerate the […]